BioArctic AB 2025 IR
The report highlights BioArctic's transition into a growth era in 2025, marked by record financial results and the expansion of its drug pipeline. Key achievements include the EU approval and launch of Leqembi, the world's first disease-modifying treatment for Alzheimer's disease, and a new collaboration with Novartis for the BrainTransporter technology. BioArctic also advanced its clinical programs, notably exidavnemab for Parkinson's disease and multiple system atrophy. In sustainability, the company aligned its reporting with the European Sustainability Reporting Standards (ESRS), committed to validating climate targets with the Science Based Targets initiative (SBTi) by 2026, and maintained 100% renewable energy in its own operations.
Company: BioArctic AB
Sector: Professional & technical services
Country: Sweden
Year: 2025
Type: IR
Pages: 187
Back to company
BioArctic AB
Annual And Sustainability Report
The report highlights BioArctic's transition into a growth era in 2025, marked by record financial results and the expansion of its drug pipeline. Key achievements include the EU approval and launch of Leqembi, the world's first disease-modifying treatment for Alzheimer's disease, and a new collaboration with Novartis for the BrainTransporter technology. BioArctic also advanced its clinical programs, notably exidavnemab for Parkinson's disease and multiple system atrophy. In sustainability, the company aligned its reporting with the European Sustainability Reporting Standards (ESRS), committed to validating climate targets with the Science Based Targets initiative (SBTi) by 2026, and maintained 100% renewable energy in its own operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees